Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

Chances are, you haven’t heard of metabolic dysfunction–associated steatohepatitis (MASH)—but you’ve almost definitely heard ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

Improvement seen in resolution of steatohepatitis without worsening of fibrosis and in fibrosis without worsening of steatohepatitis. (HealthDay News) — For patients with metabolic dysfunction ...